MA39740A - Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes - Google Patents

Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Info

Publication number
MA39740A
MA39740A MA039740A MA39740A MA39740A MA 39740 A MA39740 A MA 39740A MA 039740 A MA039740 A MA 039740A MA 39740 A MA39740 A MA 39740A MA 39740 A MA39740 A MA 39740A
Authority
MA
Morocco
Prior art keywords
compositions
methods
estrogen receptor
receptor mutants
modulating estrogen
Prior art date
Application number
MA039740A
Other languages
English (en)
Inventor
Maneval Edna Chow
Lori Friedman
Jeffrey H Hager
James D Joseph
Jing Qian
Debasish F Roychowdhury
Deepak Sampath
Nicholas D Smith
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of MA39740A publication Critical patent/MA39740A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour le traitement d'une pathologie liée à er caractérisée par une mutation dans le gène
MA039740A 2014-03-13 2015-03-12 Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes MA39740A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952728P 2014-03-13 2014-03-13
US201461981708P 2014-04-18 2014-04-18

Publications (1)

Publication Number Publication Date
MA39740A true MA39740A (fr) 2017-01-18

Family

ID=52682706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039740A MA39740A (fr) 2014-03-13 2015-03-12 Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes

Country Status (14)

Country Link
US (1) US9855270B2 (fr)
EP (1) EP3116496A1 (fr)
JP (1) JP2017509631A (fr)
KR (1) KR20160132029A (fr)
CN (1) CN106488767A (fr)
AU (1) AU2015228860A1 (fr)
BR (1) BR112016020953A2 (fr)
CA (1) CA2941161A1 (fr)
IL (1) IL247250A0 (fr)
MA (1) MA39740A (fr)
MX (1) MX2016011698A (fr)
RU (1) RU2016137150A (fr)
SG (1) SG11201607339VA (fr)
WO (1) WO2015136017A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110030A2 (fr) 2012-01-19 2013-07-25 Duke University Vaccins dirigés contre des antigènes impliqués dans la résistance à un traitement et leurs méthodes d'utilisation
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
BR112015031903A8 (pt) * 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
WO2014205136A1 (fr) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Modulateurs azétidine des récepteurs d'œstrogènes et leurs utilisations
WO2015057635A1 (fr) * 2013-10-18 2015-04-23 The Regents Of The University Of Michigan Systèmes et procédés permettant de déterminer un plan thérapeutique d'action
WO2016007499A1 (fr) 2014-07-07 2016-01-14 Duke University Vaccins contre un isoforme oncogène d'her2 (erbb2) et leurs méthodes d'utilisation
WO2016007504A1 (fr) 2014-07-07 2016-01-14 Duke University Vaccins dirigés contre une isoforme oncogène d'esr1 et leurs méthodes d'utilisation
US9783503B2 (en) 2014-08-11 2017-10-10 Genentech, Inc. Crystalline forms of an estrogen receptor modulator
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
EP3274476B1 (fr) 2015-03-25 2023-06-07 The General Hospital Corporation Analyse numérique de cellules tumorales circulantes dans des échantillons de sang
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
EP3359527A1 (fr) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Procédé pour la préparation d'acide (e)-3-(4-((e)-2-(2-chloro-4-fluorophényl)-1-(1h-indazol-5-yl)but-1-én-1-yl)phényl)acrylique
NZ743651A (en) 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
CN108697779B (zh) * 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
WO2017136688A1 (fr) 2016-02-05 2017-08-10 Inventisbio Inc. Agents de dégradation sélectifs des récepteurs des œstrogènes et leurs utilisations
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
CA3018801C (fr) * 2016-03-25 2020-06-23 Luoxin Biotechnology (Shanghai) Co., Ltd Composes a substitution indole comme agent de degradation des recepteursdes oestrogenes
JP7131773B2 (ja) 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
SG11201811564QA (en) 2016-06-29 2019-01-30 Tesaro Inc Methods of treating ovarian cancer
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
CN109790568B (zh) * 2016-08-18 2022-09-20 豪夫迈·罗氏有限公司 用于检测雌激素受体esr1突变的多路等位基因特异性pcr测定
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
PL3525774T3 (pl) * 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
CN110050075B (zh) * 2016-10-27 2024-04-02 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018148576A1 (fr) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Modulateurs du récepteur des œstrogènes de benzothiophène
CN111094227A (zh) * 2017-07-28 2020-05-01 里科瑞尔姆Ip控股有限责任公司 丙烯酸类似物
WO2019057201A1 (fr) * 2017-09-25 2019-03-28 罗欣生物科技（上海）有限公司 Forme cristalline d'un inhibiteur du récepteur des œstrogènes et son procédé de préparation
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
EP3731866A1 (fr) * 2017-12-27 2020-11-04 Tesaro Inc. Méthodes de traitement du cancer
WO2019199891A1 (fr) 2018-04-10 2019-10-17 Duke University Traitement du cancer du sein avec du lasofoxifène
IL278063B2 (en) 2018-06-21 2025-08-01 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111184863B (zh) * 2018-11-15 2023-06-16 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
KR102858291B1 (ko) 2018-11-28 2025-09-12 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드 에스트로겐 수용체 하향 조절제의 염 형태와 결정형, 및 이의 제조방법
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2020132785A1 (fr) * 2018-12-24 2020-07-02 Inventisbio Shanghai Ltd. Nouveaux sels d'agents de dégradation sélectifs du récepteur des oestrogènes
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2020165834A1 (fr) 2019-02-15 2020-08-20 Novartis Ag Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations
PY2020118A (es) 2019-05-20 2022-10-27 Servier Lab Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
KR20220024476A (ko) * 2019-06-19 2022-03-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인다졸 유도체, 이의 제조 방법, 및 이의 약제학적 적용
CN110982807B (zh) * 2019-12-17 2022-04-29 云南农业大学 一种高效稳定的纤维素酶突变体
CA3165382A1 (fr) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinaisons
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
BR112022012280A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
EP4114391B1 (fr) * 2020-03-06 2025-07-09 Olema Pharmaceuticals, Inc. Compositions à utiliser dans une méthode de traitement d'un cancer associé à des récepteurs d'oestrogènes
CN120665066A (zh) * 2020-05-15 2025-09-19 南京再明医药有限公司 吡咯烷类化合物及其应用
WO2021260528A1 (fr) 2020-06-23 2021-12-30 Novartis Ag Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CR20230283A (es) 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022245124A1 (fr) * 2021-05-18 2022-11-24 재단법인 대구경북첨단의료산업진흥재단 Nouveau composé d'éthène et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer
CN113293213A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测乳腺癌复发转移基因her2扩增的引物探针及其应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées
JP2025526784A (ja) 2022-08-11 2025-08-15 イヴクスタ・バイオ 癌を処置するための化合物
CN115820545A (zh) * 2022-12-28 2023-03-21 中国农业大学 提高卵母细胞体外成熟率的培养基及其应用
EP4676540A1 (fr) 2023-03-10 2026-01-14 Novartis AG Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025168601A1 (fr) 2024-02-05 2025-08-14 Evexta Bio Composés d'azétidine de quinazoline carboxamide destinés à être utilisés dans le traitement de maladies hormono-dépendantes
WO2025215536A1 (fr) 2024-04-10 2025-10-16 Novartis Ag Inhibiteurs de panras macrocycliques pour le traitement du cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
AU782142B2 (en) 1999-12-07 2005-07-07 Sumitomo Chemical Company, Limited Mutant ERalpha and test systems for transactivation
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (fr) * 2011-10-14 2013-04-18 Foundation Medicine, Inc. Nouvelles mutations de récepteur des estrogènes et leurs utilisations
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
EA201490897A1 (ru) * 2011-12-16 2015-03-31 Олема Фармасьютикалс, Инк. Новые бензопирановые соединения, композиции и их применение
EA201491530A1 (ru) 2012-03-20 2015-07-30 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогенов и их применение
JP2016517420A (ja) * 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
JP2016521557A (ja) * 2013-06-07 2016-07-25 キージーン・エン・フェー 標的配列決定のための方法
AU2014274730A1 (en) * 2013-06-07 2016-01-21 Rana Therapeutics, Inc. Compositions and methods for modulating FOXP3 expression
WO2014205136A1 (fr) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Modulateurs azétidine des récepteurs d'œstrogènes et leurs utilisations
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
EP3089747A1 (fr) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Modulateur du récepteur des strogènes pour le traitement du cancer du sein localement avancé ou positif aux récepteurs des strogènes métastatiques
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ

Also Published As

Publication number Publication date
WO2015136017A1 (fr) 2015-09-17
RU2016137150A3 (fr) 2018-10-19
MX2016011698A (es) 2016-12-12
RU2016137150A (ru) 2018-04-18
US9855270B2 (en) 2018-01-02
AU2015228860A1 (en) 2016-09-08
CA2941161A1 (fr) 2015-09-17
US20150258099A1 (en) 2015-09-17
IL247250A0 (en) 2016-09-29
BR112016020953A2 (pt) 2018-01-23
SG11201607339VA (en) 2016-10-28
JP2017509631A (ja) 2017-04-06
CN106488767A (zh) 2017-03-08
EP3116496A1 (fr) 2017-01-18
KR20160132029A (ko) 2016-11-16

Similar Documents

Publication Publication Date Title
MA39740A (fr) Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
IL273058A (en) Compositions and methods for modulation of PKK expression
IL271659A (en) Compositions and methods for modulating expression of complement factor B
IL272653A (en) Preparations and methods for the modulation of growth hormone receptor expression
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
GB2556286A (en) Programmable voltage reference
MA39741A (fr) Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes
TW201613966A (en) SynTac polypeptides and uses thereof
MA39819A (fr) Méthodes et compositions d'immunomodulation
SG10201900574SA (en) Virtual currency conversion device, method and computer program
EP3134120A4 (fr) Compositions et méthodes pour le traitement de troubles liés aux cytokines
EP3122872A4 (fr) Compositions et méthodes destinées à traiter le diabète de type 1 et type 2 et autres troubles associés
EP3110446A4 (fr) Procédés et compositions pour le traitement de maladies associées à siglec-8
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.
PH12017500602A1 (en) Methods for treating ocular conditions
EP3186269A4 (fr) Compositions, procédés et kits pour le traitement des troubles liés au complément
EP3194027A4 (fr) Procédés et compositions pour le traitement de troubles psychotiques
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
EP3118312A4 (fr) Procédé de fabrication de 1,5-pentadiamine mettant en uvre un mutant de lysine décarboxylase de stabilité thermique améliorée
EP3092027A4 (fr) Procédés et compositions transpapillaires pour le dignostic et le traitement de maladies du sein
EP3220946A4 (fr) Compositions et procédés de traitement de l'intolérance au gluten et des troubles qui en découlent
PL3169937T3 (pl) Aparatura do produkcji energii elektrycznej i powiązany proces
UA106748U (uk) Пристрій для формування паливних матеріалів
MX371121B (es) Composiciones para usarse en inmunomodulación.